Pharmaceutical reshoring: A healthy requirement, a strategic necessity

摘要

In March 2020, the COVID-19 crisis had just begun ... and everyone was in panic mode. Shortages of the necessary basic ingredients for pharmaceutical production and delays in shipping started a frantic discussion regarding whether global pharmaceutical supply chains had become too intricate and/or too Asia-centric. The US and Europe started to investigate how reshoring pharmaceutical manufacturing activities and national prioritisation might strengthen their supply chains. A year later, there is a new administration in the US and global sentiments continue to vary on whether reshoring is a practical long-term solution to address the health challenges that may arise in the future. Here, Andrew Badrot, CEO, C2 PHARMA, discusses the ongoing ramifications of the pandemic for the pharmaceutical industry and the global politics that go hand in hand with reshoring efforts.